Roche enters partnership with Alnylam for hypertension therapy

[July 24, 2023]  ZURICH (Reuters) - Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.

Under terms of agreement, which provides Roche with exclusive commercialisation rights outside of the United States and joint commercialisation rights within the country, Alnylam would receive an upfront payment of $310 million, Roche said.

(Reporting by Brenna Hughes Neghaiwi; Editing by Miranda Murray)

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.